Some of the cancers identified in excess here are recognized to be associated with the known cancer genes reported to be observed in 11% of Ewing sarcoma patients (TP53, RET, and PMS2); a search for pathogenic variants in some of the patients and relatives identified in this study could clarify this. This evidence concerns the gene TP53 and Ewing sarcoma.